PMGC Holdings (ELAB) Long-Term Deferred Tax (2022 - 2025)
PMGC Holdings (ELAB) posted Long-Term Deferred Tax of $5.5 million for Q4 2025, up 66.82% sequentially from $3.3 million in Q4 2024, and up 66.82% YoY from $3.3 million in Q4 2024.
PMGC Holdings (ELAB) Long-Term Deferred Tax (2022 - 2025) Analysis & Trends
PMGC Holdings has reported Long-Term Deferred Tax for 4 years, with the latest figure at $5.5 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 66.82% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (up 66.82% YoY) and the FY2025 annual result came in at $5.5 million, up 66.82% from the prior year.
- Long-Term Deferred Tax improved to $5.5 million in Q4 2025 per ELAB's latest filing, from $3.3 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $5.5 million in Q4 2025 and troughed at $662000.0 in Q4 2022.
- A 4-year average of $2.8 million and a median of $2.5 million in 2023 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax soared 158.31% in 2023, then soared 66.82% in 2025.
- Over 4 years, Long-Term Deferred Tax stood at $662000.0 in 2022, then jumped by 158.31% to $1.7 million in 2023, then surged by 94.31% to $3.3 million in 2024, then surged by 66.82% to $5.5 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $5.5 million, $3.3 million, and $1.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.54 Mn |
| Dec 31, 2024 | 3.32 Mn |
| Dec 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 662,000.00 |